Q&A with Sara McCoy on innovative treatment for Sjögren’s disease
Dr. Sara McCoy, a rheumatologist in the Department of Medicine, is one of the nation’s leading experts on Sjögren’s disease, an autoimmune disorder that affects moisture-producing glands in the eyes, mouth and other parts of the body.
Experimental cell therapy trial treats first Sjögren’s disease patient
The first person in the world to receive a dose of a novel cell therapy for a symptom of the immune disorder Sjögren’s disease has been treated during a clinical trial conducted by researchers at the University of Wisconsin School of Medicine and Public Health.
Trust is key to collaborating with Native community
From their home near the forested lakes of Mole Lake, Wisconsin, the Tribal Council of the Sokaogon Chippewa Community (SCC) traveled to the University of Wisconsin–Madison, where they were welcomed by health sciences and biomedical researchers and staff.
Q&A with Lynda S. Bader on strategy within the Clinical Trials Institute
Lynda S. Bader is the director of clinical trials strategic initiatives for the UW Clinical Trials Institute (CTI). She was recently honored with a Regents Academic Staff Excellence Award, the highest recognition bestowed by the Universities of Wisconsin, for her leadership of strategic initiatives that have greatly improved the clinical trials landscape at UW–Madison.
Partnerships Bolster Biotechnology Research and Training
In October 2023, President Joe Biden announced Wisconsin’s selection among 31 Regional Technology Hubs designated by the Economic Development Administration under the 2021 Creating Helpful Incentives to Produce Semiconductors (CHIPS) and Science Act.
UW clinical trial tests new way to treat glioblastoma
A new clinical trial at UW Health | Carbone Cancer Center uses a personalized medicine method to try to teach the immune system to recognize and destroy glioblastoma tumors.
New UW study examines COVID-19 vaccines in people with weakened immune systems
Researchers at the University of Wisconsin School of Medicine and Public Health are exploring the ideal vaccine booster strategy for immunosuppressed patients to protect those at higher risk of severe illness and complications from COVID-19 infection.
UW study examines potential treatment for Alzheimer’s disease
Researchers at the University of Wisconsin School of Medicine and Public Health are investigating whether the drug leuprolide, which is approved for prostate cancer in men, can be used to treat symptoms of Alzheimer’s disease in women.
UW study seeks IBD patients to study effectiveness of updated COVID-19 vaccines
Researchers at the University of Wisconsin School of Medicine and Public Health are investigating how well the updated monovalent COVID-19 vaccines work for inflammatory bowel disease patients.
Clinical trial for severe dry mouth treatment launching soon at UW
The UW Health | Carbone Cancer Center and UW Program for Advanced Cell Therapy, or PACT, will soon begin a clinical trial using a recently developed cell therapy to treat severe dry mouth, which is a significant symptom of graft-versus-host disease and Sjögren’s disease.
UW Health, UW School of Medicine and Public Health launch UW Clinical Trials Institute
UW Health and the UW School of Medicine and Public Health are announcing the formation of the University of Wisconsin Clinical Trials Institute to advance health care innovations via clinical trials at UW–Madison.
UW study focuses on Alzheimer’s disease treatment and prevention in Black adults
As the first of a new generation of Alzheimer’s disease drugs hit the market, some researchers are troubled by the lack of clinical data available on the effectiveness of these drugs in Black people.